Citations

Mayo Clinic

Showing 10 of 108551 citations.

Serial Bronchoalveolar Lavage Fluid Aspergillus Galactomannan and Treatment Response in Invasive Pulmonary Aspergillosis
Friedman, Daniel , Theel, Elitza S. , Walker, Randall C., Vikram, Holenarasipur R. , Vergidis, Paschalis , Vergidis, Paschalis , Vikram, Holenarasipur R. , Friedman, Daniel Z P , Razonable, Raymund R.

Open Forum Infectious Diseases | March 1, 2024 | Volume: 11 | Issue: 4 | Pages: No page available

10.1093/ofid/ofae114 | PMID 38560609 Get It

Abstract We studied patients diagnosed with aspergillosis based on positive bronchoalveolar lavage (BAL) Aspergillus galactomannan (GM) who had follow-up BAL sampling within 180 days. GM trend and clinical outcome were concordant in only 60% (30/50). While useful for the initial diagnosis, BAL GM trending does not always correlate with treatment response.
A Woman with Progressive Cough, Dyspnea, and Early Graying of Her Hair
Hu, Alan W. , Patnaik, Mrinal M. , Kelm, Diana J. , Hu, Alan

Annals of the American Thoracic Society | March 1, 2024 | Volume: 21 | Issue: 3 | Pages: 499-503

10.1513/annalsats.202304-336cc | PMID 38426822 Get It

Successful treatment of severe passenger lymphocyte syndrome with efgartigimod synergy
Chase, R. Christopher , Koop, Andree , Shaikh, Marwan , Imperial, Robin, Harnois, Denise M. , Loo, Nicole , OʼBrien, Jennifer , Imperial, Robin J, Loo, Nicole M, O'Brien, Jennifer J, Chase, R Christopher

Transfusion | March 1, 2024 | Volume: 64 | Issue: 4 | Pages: 755-760

10.1111/trf.17748 | PMID 38425280 Get It

AbstractIntroductionThis case describes passenger lymphocyte syndrome (PLS) generating human platelet antigen 1a (HPA‐1a) alloantibodies against the recipient's platelets after liver transplant. Given the rarity of PLS, especially in liver transplant with HPA‐1a alloantibodies, disease course and management options are poorly described.MethodsThe patient had cirrhosis secondary to nonalcoholic steatohepatitis complicated by hepatocellular carcinoma, encephalopathy, and severe ascites. The model for end‐stage liver disease (MELD) score was 15 at presentation. The patient developed hepatic artery thrombosis after an orthotopic liver transplant and was relisted for transplant with a MELD score of 40. The patient received a hepatitis C virus antibody positive, hepatitis C virus nucleic amplification test positive donor liver on postoperative day (POD) 7 after first transplant. On POD 7 after the second transplant, the patient developed profound thrombocytopenia refractory to platelet infusion. They were found to have serum antibody to HPA‐1a based upon serum platelet alloantibody testing. The donor was later found to be negative for HPA‐1a by genetic testing. However, the patient's native platelets were HPA‐1a positive. The patient was diagnosed with PLS.ResultsThe patient's treatment course included 57 units of platelets transfused, emergency splenectomy, rituximab, plasma exchange, intravenous immunoglobulin (IVIG), eltrombopag, romiplostim, and efgartigimod.DiscussionThe synergistic effect of efgartigimod with eltrombopag and romiplostim most likely resolved the patient's thrombocytopenia. This case represents a novel use of efgartigimod in the treatment of passenger lymphocyte syndrome following liver transplant.
A practical guide to the development and deployment of deep learning models for the orthopaedic surgeon: Part III, focus on registry creation, diagnosis, and data privacy
Oeding, Jacob F. , Yang, Linjun , Samuelsson, Kristian , Pearle, Andrew D. , Kelly, Bryan T. , Pareek, Ayoosh , Yang, Linjun , Sanchez-Sotelo, Joaquin, Samuelsson, Kristian , Oeding, Jacob F , Yang, Linjun , Sánchez‐Sotelo, Joaquín , Camp, Christopher L. , Karlsson, Jón , Ranawat, Anil S.

Knee Surgery, Sports Traumatology, Arthroscopy | March 1, 2024 | Volume: 32 | Issue: 3 | Pages: 518-528

10.1002/ksa.12085 | PMID 38426614 Get It

AbstractDeep learning is a subset of artificial intelligence (AI) with enormous potential to transform orthopaedic surgery. As has already become evident with the deployment of Large Language Models (LLMs) like ChatGPT (OpenAI Inc.), deep learning can rapidly enter clinical and surgical practices. As such, it is imperative that orthopaedic surgeons acquire a deeper understanding of the technical terminology, capabilities and limitations associated with deep learning models. The focus of this series thus far has been providing surgeons with an overview of the steps needed to implement a deep learning‐based pipeline, emphasizing some of the important technical details for surgeons to understand as they encounter, evaluate or lead deep learning projects. However, this series would be remiss without providing practical examples of how deep learning models have begun to be deployed and highlighting the areas where the authors feel deep learning may have the most profound potential. While computer vision applications of deep learning were the focus of Parts I and II, due to the enormous impact that natural language processing (NLP) has had in recent months, NLP‐based deep learning models are also discussed in this final part of the series. In this review, three applications that the authors believe can be impacted the most by deep learning but with which many surgeons may not be familiar are discussed: (1) registry construction, (2) diagnostic AI and (3) data privacy. Deep learning‐based registry construction will be essential for the development of more impactful clinical applications, with diagnostic AI being one of those applications likely to augment clinical decision‐making in the near future. As the applications of deep learning continue to grow, the protection of patient information will become increasingly essential; as such, applications of deep learning to enhance data privacy are likely to become more important than ever before.Level of Evidence: Level IV.
A Practical Guide to Whole Genome Sequencing in the NICU
Seither, Katelyn , Thompson, Whitney, Suhrie, Kristen

NeoReviews | March 1, 2024 | Volume: 25 | Issue: 3 | Pages: e139-e150

10.1542/neo.25-3-e139 | PMID 38425198 Get It

Abstract The neonatal period is a peak time for the presentation of genetic disorders that can be diagnosed using whole genome sequencing (WGS). While any one genetic disorder is individually rare, they collectively contribute to significant morbidity, mortality, and health-care costs. As the cost of WGS continues to decline and becomes increasingly available, the ordering of rapid WGS for NICU patients with signs or symptoms of an underlying genetic condition is now feasible. However, many neonatal clinicians are not comfortable with the testing, and unfortunately, there is a dearth of geneticists to facilitate testing for every patient that needs it. Here, we will review the science behind WGS, diagnostic capabilities, limitations of testing, time to consider testing, test initiation, interpretation of results, developing a plan of care that incorporates genomic information, and returning WGS results to families.
Clinical and radiological features of parasagittal dural arteriovenous fistulas: a report of 8 cases from a single institution
Cloft, Harry J. , Brinjikji, Waleed , Alexander, A. Yohan, Patel, Nitesh P. , Lanzino, Giuseppe

Neurosurgical Focus | March 1, 2024 | Volume: 56 | Issue: 3 | Pages: E16

10.3171/2023.12.focus23792 | PMID 38427987 Get It

OBJECTIVE Dural arteriovenous fistulas (dAVFs) of the superior sagittal sinus (SSS) are uncommon and represent 5%–12% of all intracranial dAVFs. SSS dAVFs can be divided into two main subtypes. The first type involves direct arterialization of the SSS, whereas the second type consists of a parasagittal arteriovenous shunt draining into a cortical vein directly lateral to the SSS and has retrograde cortical venous drainage with only secondary involvement of the SSS. Descriptions of the latter type of SSS dAVF are limited. As such, the authors present a consecutive case series of parasagittal SSS dAVFs from their institution. They detail clinical presentation, treatment strategies, and clinical and radiographic outcomes. METHODS The authors retrospectively reviewed a prospectively collected database of dAVFs that were treated between 2017 and 2023. All dAVFs characterized by an arterialized parasagittal vein directly lateral to the SSS were included in this study. Baseline demographic, clinical, radiological, treatment, and outcome-specific variables of interest were abstracted. RESULTS One hundred fifty-four dAVFs were seen at the authors’ institution over the 6-year period of interest. Eight (5.2%) were parasagittal dAVFs. At initial diagnostic imaging, 7 were Cognard grade III and 1 was grade IV. All patients initially underwent embolization of their dAVF. Three patients did not have complete obliteration of their dAVF after the first embolization. One patient underwent further treatment with repeat embolization, and 1 underwent microsurgical disconnection—both resulted in complete occlusion of the dAVF. Seven dAVFs were obliterated at final follow-up and 1 remained patent as the patient refused further treatment despite angiographic progression of dAVF. All symptomatic patients had resolution of their symptoms, and the average length of follow-up was 16.8 months. CONCLUSIONS Treatment of parasagittal dAVFs consists of occluding the proximal portion of the parasagittal arterialized draining vein. Endovascular therapy with liquid embolic agents is usually the first line of treatment. Surgical ligation is a valid option if the fistula cannot be successfully obliterated with embolization. Symptoms related to the SSS dAVF resolve after their obliteration.
Dural arteriovenous fistulas are not observed to convert to a higher grade after partial embolization
Walker, Erin , Srienc, Anja I. , Lew, Daphne , Guniganti, Ridhima , Brinjikji, Waleed , Hayakawa, M. , Samaniego, Edgar A. , Lai, Rosalind, Sheehan, Jason P. , Starke, Robert M., Abla, Adib A. , Gross, Bradley A. , Albuquerque, Felipe C , Lawton, Michael T. , Kim, Louis J. , Levitt, Michael R. , Alaraj, Ali , Winkler, Ethan A. , Polifka, Adam , Bulters, Diederik , Durnford, Andrew , Satomi, Junichiro, Tada, Yoshiteru , Dijk, J. Marc C. van , Potgieser, Adriaan R. E., Zipfel, Gregory J. , Levitt, Michael R , Alaraj, Ali , Samaniego, Edgar A , van DijK, J Marc C , Abla, Adib , Bulters, Diederik O , Lanzino, Giuseppe , Derdeyn, Colin P. , Du, Rose , Abdelsalam, Ahmed , Gross, Bradley , Kim, Louis J. , Amin-Hanjani, Sepideh , Fox, W Christopher , Hall, Samuel , Chen, Ching‐Jen , Becerril‐Gaitan, Andrea , Osbun, Joshua W

Neurosurgical Focus | March 1, 2024 | Volume: 56 | Issue: 3 | Pages: E8

10.3171/2024.1.focus23745 | PMID 38428013 Get It

OBJECTIVE Borden-Shucart type I dural arteriovenous fistulas (dAVFs) lack cortical venous drainage and occasionally necessitate intervention depending on patient symptoms. Conversion is the rare transformation of a low-grade dAVF to a higher grade. Factors associated with increased risk of dAVF conversion to a higher grade are poorly understood. The authors hypothesized that partial treatment of type I dAVFs is an independent risk factor for conversion. METHODS The multicenter Consortium for Dural Arteriovenous Fistula Outcomes Research database was used to perform a retrospective analysis of all patients with type I dAVFs. RESULTS Three hundred fifty-eight (33.2%) of 1077 patients had type I dAVFs. Of those 358 patients, 206 received endovascular treatment and 131 were not treated. Two (2.2%) of 91 patients receiving partial endovascular treatment for a low-grade dAVF experienced conversion to a higher grade, 2 (1.5%) of 131 who were not treated experienced conversion, and none (0%) of 115 patients who received complete endovascular treatment experienced dAVF conversion. The majority of converted dAVFs localized to the transverse-sigmoid sinus and all received embolization as part of their treatment. CONCLUSIONS Partial treatment of type I dAVFs does not appear to be significantly associated with conversion to a higher grade.
The negative impact of treatment delays on the long-term neurological outcomes of spinal dural arteriovenous fistulas: a longitudinal cohort study
El-Hajj, Victor Gabriel , Daller, Cornelia, Fletcher‐Sandersjöö, Alexander , Gharios, Maria , Bydon, Mohamad , Söderman, Michael , Elmi‐Terander, Adrian , Arnberg, Fabian , Elmi-Terander, Adrian , El-Hajj, Victor Gabriel , Jabbour, Pascal , Edström, Erik

Neurosurgical Focus | March 1, 2024 | Volume: 56 | Issue: 3 | Pages: E14

10.3171/2023.12.focus23703 | PMID 38427990 Get It

OBJECTIVE Dural arteriovenous fistulas are rare vascular malformations that affect the brain and spinal cord. Spinal dural arteriovenous fistulas (sdAVFs) are the most frequently encountered vascular malformation affecting the spinal cord. The object of this study was to evaluate the impact of treatment delays on the long-term neurological outcomes of either open surgical or interventional treatment of sdAVFs. METHODS In this retrospective, population-based cohort study, the authors examined consecutive patients with diagnosed sdAVFs at a tertiary care center between 2005 and 2020. Patients were assessed using the Aminoff-Logue disability scale (ALS) at various time points including symptom onset, primary care visit, first specialist outpatient visit, as well as both short and long-term follow-ups. The postoperative long-term ALS gait and bladder grades constituted the primary outcomes of the study. RESULTS Among the 34 patients included in the study, the median age was 65 years, and there was a male predominance (71%). Most lesions were in the lumbar region (47%). Significant worsening in ALS gait and bladder grades was observed preoperatively, followed by postoperative improvements (p < 0.05). There was no difference in outcomes between surgical and endovascular treatments. Older age (OR 1.10, 95% CI 1.03–1.17, p = 0.007), worse preoperative ALS gait grades (OR 5.12, 95% CI 2.18–12.4, p < 0.001), and longer time from first specialist outpatient visit to first treatment (OR 1.00, 95% CI 1.00–1.01, p = 0.040) were independently associated with worse long-term gait outcomes. Only the preoperative ALS bladder score was a predictor of worse long-term bladder function (OR 92.7, 95% CI 28.0–306.7, p < 0.001). CONCLUSIONS Both surgical and endovascular treatments for sdAVFs led to significant neurological improvements. However, treatment delays were associated with less favorable long-term outcomes. Prompt diagnosis and early intervention prior to symptom progression may enhance recovery and help to preserve neurological function.
Safety evaluation of sinus patency after stereotactic radiosurgery for transverse–sigmoid sinus dural arteriovenous fistulas: implications of treatment options for patients with Borden type I fistulas
Umekawa, Motoyuki , Shinya, Yuki , Hasegawa, Hirotaka , Katano, Atsuto , Shinya, Yuki , Koizumi, Satoshi , Saito, Nobuhito

Neurosurgical Focus | March 1, 2024 | Volume: 56 | Issue: 3 | Pages: E12

10.3171/2023.12.focus23802 | PMID 38427991 Get It

OBJECTIVE This study aimed to assess the efficacy and safety of stereotactic radiosurgery (SRS) in treating transverse–sigmoid sinus dural arteriovenous fistulas (TSS DAVFs), and to investigate post-SRS sinus patency, focusing on the risk factors associated with treated sinus occlusion. METHODS Data from 34 patients treated with SRS between January 2006 and April 2023 were analyzed. Detailed angioarchitecture was confirmed using digital subtraction angiography before SRS. Angiography of the ipsilateral internal carotid artery and vertebral artery was performed to evaluate whether the involved side of the TSS was used for normal venous drainage. TSS stenosis was defined as sinus diameter < 50% of the normal proximal diameter. DAVF shunt obliteration, TSS occlusion, neurological status, and adverse events were also evaluated. RESULTS Of the 34 patients, 21 had Borden type I and 14 had Borden type II DAVFs. The median age at SRS was 64 years (interquartile range 54–71 years), and the follow-up period was 31 months (interquartile range 15–94 months). Complete shunt obliteration was achieved in 24 (70.6%) patients. The cumulative 2-, 3-, and 5-year shunt obliteration rates were 49.6%, 71.2%, and 86.0%, respectively. Borden type I had higher obliteration rates (60.5%, 83.1%, and 94.4%, respectively) than Borden type II (41.7%, 51.4%, and 75.7%, respectively; p = 0.034). TSS occlusion occurred in 5 patients (14.7%). The cumulative 1-, 5-, and 10-year TSS occlusion rates were 2.9%, 8.3%, and 23.6%, respectively, across the entire cohort. All occlusions occurred exclusively in the sinuses that were not used for normal venous drainage. Cox proportional analyses revealed that TSS stenosis and the sinus not being used for normal venous drainage were significantly associated with a greater risk of TSS occlusion after SRS (HR 9.44, 95% CI 1.01–77.13; p = 0.049). CONCLUSIONS SRS is effective and safe for TSS DAVF and results in favorable shunt obliteration, symptom improvement, and low complication rates. TSS occlusion after SRS is asymptomatic and is limited to sinuses that are not used for normal venous drainage.
Gut Mycobiome and Asthma
Kanj, Amjad , Skalski, Joseph H. , Kanj, Amjad N

Journal of Fungi | March 1, 2024 | Volume: 10 | Issue: 3 | Pages: 192

10.3390/jof10030192 | PMID 38535201 Get It

This review explores the ‘gut–lung axis’ in asthma with a focus on commensal fungal organisms. We explore how changes to the intestinal commensal fungal community composition alter lung immune function. We comprehensively review available studies that have profiled the composition of the gut mycobiome in adults and children with asthma, and discuss mechanisms of gut–lung interactions that have been described in animal models of asthma. Studies indicate that intestinal fungal dysbiosis, such as an increased abundance of certain fungi like Candida, can elevate the risk of asthma in children and exacerbate it in adults. This effect is mediated through various pathways: the host immune system’s sensing of dysbiosis via C-type lectin receptors (e.g., Dectin-2), the impact of pro-inflammatory fungal metabolites (e.g., 12,13-diHOME, prostaglandin E2), and the role of lung immune cells (e.g., group 2 innate lymphoid cells [ILC2], M2 macrophages). We also describe strategies for modulating the gut mycobiome as potential therapies for severe asthma. The review concludes by emphasizing the necessity for further research into the role of the gut mycobiome in asthma to deepen our understanding of these complex interactions.